1445700-01-5
Chemical Structure
TFMB-(R)-2-HG
- CAS No.: 1445700-01-5
- Formula:C13H11F3O4
- Molecular Weight:288.22
IUPAC Name: 3-(trifluoromethyl)benzyl (R)-5-oxotetrahydrofuran-2-carboxylate
InChIKey: UXTLNUGKDZMPTC-SNVBAGLBSA-N
SMILES: O=C([C@@H](CC1)OC1=O)OCC2=CC=CC(C(F)(F)F)=C2
Biological Activity: TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TFMB-(R)-2-HG | 98.26% | TFMB-(R)-2-HG is a cell membrane-permeable (R)-2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB-(R)-2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB-(R)-2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB-(R)-2-HG is used in acute myeloid leukemia and glioma research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-129079ATFMB-(S)-2-HG -
Similarity Score 0.60
HY-175154(1S,3S)-3-Hydroxycyclopentane carboxylic acid benzyl ester -
Similarity Score 0.60
HY-175161(1R,3S)-3-Hydroxycyclopentane carboxylic acid benzyl ester -
Similarity Score 0.60
HY-W088558Benzyl (1R,3R)-3-hydroxycyclopentane-1-carboxylate -
Similarity Score 0.56
HY-W0754245-(Trifluoromethyl)isophthalic acid -
Similarity Score 0.56
HY-20003(-)-Corey lactone benzoate -
Similarity Score 0.55
HY-23507R5-Methoxy-1-(4-(trifluoromethyl)phenyl)pentan-1-one (Standard) -
Similarity Score 0.55
HY-1331005-ALA benzyl ester hydrochloride -
Similarity Score 0.55
HY-30232L-Glutamate-γ-benzyl ester -
Explore the MedChemAI to find more analogs
References
- [1]. Losman JA, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29;339(6127):1621-5. [Content Brief]
- [2]. Philip B, et al. Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep. 2018 May 1;23(5):1553-1564. [Content Brief]
- [3]. Gunn K, et al. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 Jun 2;13(6):1478-1497. [Content Brief]
